Country data on AMR in India in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action. To review the current situation with respect to AMR in India and initiatives addressing it. Identifying areas where more information is required will provide a call to action to minimize further rises in AMR and to improve patient outcomes. National AMR initiatives, antibiotic use and prescribing in India, and availability of susceptibility data, in particular for the key community-acquired respiratory tract infection (CA-RTI) pathogens (Streptococcus pneumoniae and Haemophilus influenzae) were identified. National and international antibiotic prescribing guidelines for specific CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) commonly used locally were also reviewed, plus local antibiotic availability. Insights from a local clinician and clinical microbiologist were sought to contextualize this information. Many initiatives have been launched since AMR was recognized as a national priority and organizations such as the Indian Academy of Paediatrics and the Global Antibiotic Resistance Partnership have worked to build awareness. The Indian Ministry of Health and Family Welfare published a 5 year national action plan on AMR. However, the burden of infectious disease and consumption of antibiotics in India is high. There have been national surveillance studies generating local data along with international studies such as Survey of Antibiotic Resistance (SOAR) and Antimicrobial Testing Leadership and Surveillance (ATLAS). For common RTIs, clinicians use a range of international and national guidelines. However, a more standardized inclusive approach to developing local guidelines, using up-to-date local surveillance data from community-acquired infections, could make guidelines more locally relevant. This would encourage more appropriate antibiotic prescribing and improve adherence. This would, in turn, potentially limit AMR development and improve patient outcomes.
Sections du résumé
BACKGROUND
Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action.
OBJECTIVES
To review the current situation with respect to AMR in India and initiatives addressing it. Identifying areas where more information is required will provide a call to action to minimize further rises in AMR and to improve patient outcomes.
METHODS
National AMR initiatives, antibiotic use and prescribing in India, and availability of susceptibility data, in particular for the key community-acquired respiratory tract infection (CA-RTI) pathogens (Streptococcus pneumoniae and Haemophilus influenzae) were identified. National and international antibiotic prescribing guidelines for specific CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) commonly used locally were also reviewed, plus local antibiotic availability. Insights from a local clinician and clinical microbiologist were sought to contextualize this information.
CONCLUSIONS
Many initiatives have been launched since AMR was recognized as a national priority and organizations such as the Indian Academy of Paediatrics and the Global Antibiotic Resistance Partnership have worked to build awareness. The Indian Ministry of Health and Family Welfare published a 5 year national action plan on AMR. However, the burden of infectious disease and consumption of antibiotics in India is high. There have been national surveillance studies generating local data along with international studies such as Survey of Antibiotic Resistance (SOAR) and Antimicrobial Testing Leadership and Surveillance (ATLAS). For common RTIs, clinicians use a range of international and national guidelines. However, a more standardized inclusive approach to developing local guidelines, using up-to-date local surveillance data from community-acquired infections, could make guidelines more locally relevant. This would encourage more appropriate antibiotic prescribing and improve adherence. This would, in turn, potentially limit AMR development and improve patient outcomes.
Identifiants
pubmed: 36065726
pii: 6692265
doi: 10.1093/jac/dkac212
pmc: PMC9445854
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
i10-i17Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
J Antimicrob Chemother. 2022 Sep 6;77(Supplement_1):i2-i9
pubmed: 36065724
J Antimicrob Chemother. 2002 Jan;49(1):31-40
pubmed: 11751764
Lung India. 2012 Jul;29(Suppl 2):S27-62
pubmed: 23019384
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Pediatrics. 2013 Jul;132(1):e262-80
pubmed: 23796742
J Antimicrob Chemother. 2016 May;71 Suppl 1:i3-19
pubmed: 27048580
Bull World Health Organ. 2018 Feb 1;96(2):135-137
pubmed: 29403117
Clin Microbiol Infect. 2004 Apr;10 Suppl 2:18-27
pubmed: 14759230
J Antimicrob Chemother. 2016 May;71 Suppl 1:i85-91
pubmed: 27048585
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
J Family Med Prim Care. 2019 Jun;8(6):1828-1834
pubmed: 31334140
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
Glob Health Med. 2019 Dec 31;1(2):61-64
pubmed: 33330756
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
pubmed: 17630331
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Clin Infect Dis. 2012 Apr;54(8):e72-e112
pubmed: 22438350
Thorax. 2011 Oct;66 Suppl 2:ii1-23
pubmed: 21903691
Thorax. 2009 Oct;64 Suppl 3:iii1-55
pubmed: 19783532
Clin Infect Dis. 2011 Oct;53(7):e25-76
pubmed: 21880587